NEW YORK, Sept. 30, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (“MindMed” or the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately. Mr. Krebs is an internationally experienced…


Previous articleMINDCURE Announces Commencement of Trading on the OTCQX Best Market
Next articlePTSF79 – Psychedelic Facilitator Abuse and Space Holding Ethics with Dr. Ido Cohen